Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma

The 2019 annual meetings of the American Society of Clinical Oncology and the European Hematology Association took place, respectively, in Chicago, Illinois, 31 May-4 June, and in Amsterdam, Netherlands, 13-16 June. At the meetings, results from key studies on the treatment of patients with relapsed...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2019-08, Vol.26 (4), p.e581-594
Main Authors: LeBlanc, R, Song, K, White, D, Christofides, A, Doucette, S
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Canada
Chromosome Deletion
Cytogenetic Analysis
Humans
Meeting Report
Multiple Myeloma - drug therapy
Multiple Myeloma - genetics
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - genetics
Prognosis
Translocation, Genetic
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 2019 annual meetings of the American Society of Clinical Oncology and the European Hematology Association took place, respectively, in Chicago, Illinois, 31 May-4 June, and in Amsterdam, Netherlands, 13-16 June. At the meetings, results from key studies on the treatment of patients with relapsed or refractory multiple myeloma with high-risk cytogenetics were presented. Our meeting report describes those studies and includes interviews with investigators and commentaries by Canadian hematologists about the potential impact on Canadian practice.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3747/co.26.5565